MorphoSys slims down, narrowing its focus to cancer

MorphoSys seemingly inexorable shift into an oncology pure-play has continued with an out-licensing deal for two programmes in the kidney disease and immunology categories to HIBio.

Incyte, MorphoSys' CAR-T rival tafasitamab approved in EU

Incyte and MorphoSys' antibody therapy tafasitamab has been approved in Europe, promising to provide a more convenient alternative to expensive and cumbersome CAR-T therapies for patients w

MorphoSys offers $1.7bn for Constellation, but investors see...

Shares in German biotech MorphoSys have gone on the slide after it announced a $1.7 billion deal to buy its US rival Constellation Pharma and its pipeline of cancer and haematology therapie

Incyte/Morphosys take on CAR-Ts with $198,000 per year antib...

Incyte and Morphosys’ Monjuvi antibody therapy has been approved for certain patients with lymphoma, as the companies hope to provide a more convenient alternative to expensive and cumberso

MorphoSys gets $750m from Incyte for anti-CD19 cancer drug

Novartis’ $100m bet on eczema drug fails as MOR106 developme...

Galapagos and MorphoSys have announced that they are ending the clinical development programme for their drug MOR106 in atopic dermatitis (also known as eczema).